{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:39:58Z","timestamp":1790746798202,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41375-025-02576-9","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T06:31:10Z","timestamp":1743402670000},"page":"1218-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-3335","authenticated-orcid":false,"given":"Hiroyuki","family":"Takamori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehito","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-5374","authenticated-orcid":false,"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-0992","authenticated-orcid":false,"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Yung","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"2576_CR1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.26751","volume":"98","author":"J Thiele","year":"2023","unstructured":"Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, et al. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023;98:166\u201379.","journal-title":"Am J Hematol"},{"key":"2576_CR2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2576_CR3","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00878-8","volume":"13","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Alkhateeb H, Gangat N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J. 2023;13. 108.","journal-title":"Blood Cancer J"},{"key":"2576_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5.e366.","journal-title":"Blood Cancer J"},{"key":"2576_CR5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019;94:599\u2013610.","journal-title":"Mayo Clin Proc"},{"key":"2576_CR6","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","volume":"27","author":"CS Tam","year":"2009","unstructured":"Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27:5587\u201393.","journal-title":"J Clin Oncol"},{"key":"2576_CR7","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0095-2","volume":"8","author":"M Mudireddy","year":"2018","unstructured":"Mudireddy M, Gangat N, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. Blood Cancer J. 2018;8:57.","journal-title":"Blood Cancer J"},{"key":"2576_CR8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018;32:1200\u201310.","journal-title":"Leukemia"},{"key":"2576_CR9","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","volume":"121","author":"JA Kennedy","year":"2013","unstructured":"Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood. 2013;121:2725\u201333.","journal-title":"Blood"},{"key":"2576_CR10","doi-asserted-by":"publisher","unstructured":"Patel AA, Yoon JJ, Johnston H, Davidson MB, Shallis RM, Chen EC, et al. Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era. Blood Adv. 2024. https:\/\/doi.org\/10.1182\/bloodadvances.2024012880.","DOI":"10.1182\/bloodadvances.2024012880"},{"key":"2576_CR11","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"2576_CR12","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220\u20138.","journal-title":"Blood"},{"key":"2576_CR13","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861\u20139.","journal-title":"Leukemia"},{"key":"2576_CR14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1:105\u201311.","journal-title":"Blood Adv"},{"key":"2576_CR15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2017.06.002","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Vannucchi AM. Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clin Proc. 2017;92:1283\u201390.","journal-title":"Mayo Clin Proc"},{"key":"2576_CR16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21\u201330.","journal-title":"Blood Adv"},{"key":"2576_CR17","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMra1910138","volume":"381","author":"J Nangalia","year":"2019","unstructured":"Nangalia J, Campbell PJ. Genome Sequencing during a Patient\u2019s Journey through Cancer. N Engl J Med. 2019;381:2145\u201356.","journal-title":"N Engl J Med"},{"key":"2576_CR18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","volume":"384","author":"EJ Duncavage","year":"2021","unstructured":"Duncavage EJ, Schroeder MC, O\u2019Laughlin M, Wilson R, MacMillan S, Bohannon A, et al. Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. N Engl J Med. 2021;384:924\u201335.","journal-title":"N Engl J Med"},{"key":"2576_CR19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/leu.2014.289","volume":"29","author":"EK Engle","year":"2015","unstructured":"Engle EK, Fisher DAC, Miller CA, McLellan MD, Fulton RS, Moore DM, et al. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia. 2015;29:869\u201376.","journal-title":"Leukemia"},{"key":"2576_CR20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","volume":"602","author":"N Williams","year":"2022","unstructured":"Williams N, Lee J, Mitchell E, Moore L, Baxter EJ, Hewinson J, et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature. 2022;602:162\u20138.","journal-title":"Nature"},{"key":"2576_CR21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2576_CR22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41375-023-01886-0","volume":"37","author":"N Maslah","year":"2023","unstructured":"Maslah N, Benajiba L, Giraudier S, Kiladjian J-J, Cassinat B. Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. Leukemia. 2023;37:957\u201363.","journal-title":"Leukemia"},{"key":"2576_CR23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2643-3230.BCD-21-0128","volume":"3","author":"T Guess","year":"2022","unstructured":"Guess T, Potts CR, Bhat P, Cartailler JA, Brooks A, Holt C, et al. Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia. Blood Cancer Discov. 2022;3:316\u201329.","journal-title":"Blood Cancer Discov"},{"key":"2576_CR24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-44158-2","volume":"15","author":"J Mitchell","year":"2024","unstructured":"Mitchell J, Milite S, Bartram J, Walker S, Volkova N, Yavorska O, et al. Clinical application of tumour-in-normal contamination assessment from whole genome sequencing. Nat Commun. 2024;15:323.","journal-title":"Nat Commun"},{"key":"2576_CR25","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/leu.2013.302","volume":"28","author":"E Tenedini","year":"2014","unstructured":"Tenedini E, Bernardis I, Artusi V, Artuso L, Roncaglia E, Guglielmelli P, et al. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia. 2014;28:1052\u20139.","journal-title":"Leukemia"},{"key":"2576_CR26","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13892-x","volume":"11","author":"E Mylonas","year":"2020","unstructured":"Mylonas E, Yoshida K, Frick M, Hoyer K, Christen F, Kaeda J, et al. Single-cell analysis based dissection of clonality in myelofibrosis. Nat Commun. 2020;11:73.","journal-title":"Nat Commun"},{"key":"2576_CR27","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2020010402","volume":"138","author":"C Marcault","year":"2021","unstructured":"Marcault C, Zhao L-P, Maslah N, Verger E, Daltro de Oliveira R, Soret-Dulphy J, et al. Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms. Blood. 2021;138:2142\u20138.","journal-title":"Blood"},{"key":"2576_CR28","doi-asserted-by":"crossref","first-page":"10715","DOI":"10.1074\/jbc.M007846200","volume":"276","author":"HL Hung","year":"2001","unstructured":"Hung HL, Kim AY, Hong W, Rakowski C, Blobel GA. Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-mediated acetylation. J Biol Chem. 2001;276:10715\u201321.","journal-title":"J Biol Chem"},{"key":"2576_CR29","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1084\/jem.20120521","volume":"210","author":"JS Jutzi","year":"2013","unstructured":"Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, et al. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med. 2013;210:1003\u201319.","journal-title":"J Exp Med"},{"key":"2576_CR30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","volume":"127","author":"X Cabagnols","year":"2016","unstructured":"Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127:333\u201342.","journal-title":"Blood"},{"key":"2576_CR31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","volume":"127","author":"JD Milosevic Feenstra","year":"2016","unstructured":"Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127:325\u201332.","journal-title":"Blood"},{"key":"2576_CR32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ni1358","volume":"7","author":"H Hu","year":"2006","unstructured":"Hu H, Wang B, Borde M, Nardone J, Maika S, Allred L, et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol. 2006;7:819\u201326.","journal-title":"Nat Immunol"},{"key":"2576_CR33","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1182\/blood-2008-01-137018","volume":"112","author":"C Shi","year":"2008","unstructured":"Shi C, Sakuma M, Mooroka T, Liscoe A, Gao H, Croce KJ, et al. Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function. Blood. 2008;112:4699\u2013711.","journal-title":"Blood"},{"key":"2576_CR34","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1101\/gad.1929210","volume":"24","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Li S, Yuan L, Tian Y, Weidenfeld J, Yang J, et al. Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes Dev. 2010;24:1746\u201357.","journal-title":"Genes Dev"},{"key":"2576_CR35","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1242\/dev.079699","volume":"139","author":"S Li","year":"2012","unstructured":"Li S, Wang Y, Zhang Y, Lu MM, DeMayo FJ, Dekker JD, et al. Foxp1\/4 control epithelial cell fate during lung development and regeneration through regulation of anterior gradient 2. Development. 2012;139:2500\u20139.","journal-title":"Development"},{"key":"2576_CR36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2015.299","volume":"30","author":"PJ Brown","year":"2016","unstructured":"Brown PJ, Wong KK, Felce SL, Lyne L, Spearman H, Soilleux EJ, et al. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia. 2016;30:605\u201316.","journal-title":"Leukemia"},{"key":"2576_CR37","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-840","volume":"14","author":"S Ackermann","year":"2014","unstructured":"Ackermann S, Kocak H, Hero B, Ehemann V, Kahlert Y, Oberthuer A, et al. FOXP1inhibits cell growth and attenuates tumorigenicity of neuroblastoma. BMC Cancer. 2014;14:840.","journal-title":"BMC Cancer"},{"key":"2576_CR38","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1210\/me.2014-1171","volume":"28","author":"K-I Takayama","year":"2014","unstructured":"Takayama K-I, Suzuki T, Tsutsumi S, Fujimura T, Takahashi S, Homma Y, et al. Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. Mol Endocrinol. 2014;28:2012\u201324.","journal-title":"Mol Endocrinol"},{"key":"2576_CR39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","volume":"118","author":"T Klampfl","year":"2011","unstructured":"Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011;118:167\u201376.","journal-title":"Blood"},{"key":"2576_CR40","first-page":"3610","volume":"10","author":"X Shao","year":"2018","unstructured":"Shao X, Wei X. FOXP1 enhances fibrosis via activating Wnt\/\u03b2-catenin signaling pathway in endometriosis. Am J Transl Res. 2018;10:3610\u20138.","journal-title":"Am J Transl Res"},{"key":"2576_CR41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/CIRCULATIONAHA.119.039767","volume":"140","author":"J Liu","year":"2019","unstructured":"Liu J, Zhuang T, Pi J, Chen X, Zhang Q, Li Y, et al. Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-\u03b21-Endothelin-1 Signal Pathway. Circulation. 2019;140:665\u201380.","journal-title":"Circulation"},{"key":"2576_CR42","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","volume":"115","author":"PA Beer","year":"2010","unstructured":"Beer PA, Delhommeau F, LeCou\u00e9dic J-P, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115:2891\u20132900.","journal-title":"Blood"},{"key":"2576_CR43","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","volume":"6","author":"TA Knudsen","year":"2022","unstructured":"Knudsen TA, Skov V, Stevenson K, Werner L, Duke W, Laurore C, et al. Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses. Blood Adv. 2022;6:2107\u201319.","journal-title":"Blood Adv"},{"key":"2576_CR44","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3324\/haematol.2013.084160","volume":"98","author":"C P\u00e9rez","year":"2013","unstructured":"P\u00e9rez C, Pascual M, Mart\u00edn-Subero JI, Bellosillo B, Segura V, Delabesse E, et al. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica. 2013;98:1414\u201320.","journal-title":"Haematologica"},{"key":"2576_CR45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","volume":"364","author":"A Harutyunyan","year":"2011","unstructured":"Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. P53 lesions in leukemic transformation. N Engl J Med. 2011;364:488\u201390.","journal-title":"N Engl J Med"},{"key":"2576_CR46","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","volume":"119","author":"S-J Zhang","year":"2012","unstructured":"Zhang S-J, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119:4480\u20135.","journal-title":"Blood"},{"key":"2576_CR47","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1182\/bloodadvances.2020002271","volume":"4","author":"D Luque Paz","year":"2020","unstructured":"Luque Paz D, Jouanneau-Courville R, Riou J, Ianotto J-C, Boyer F, Chauveau A, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4:4887\u201397.","journal-title":"Blood Adv"},{"key":"2576_CR48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","volume":"93","author":"G Venton","year":"2018","unstructured":"Venton G, Courtier F, Charbonnier A, D\u2019incan E, Saillard C, Mohty B, et al. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol. 2018;93:330\u20138.","journal-title":"Am J Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02576-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02576-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02576-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:46:36Z","timestamp":1746531996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02576-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2576"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02576-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SO reports a leadership position and advisory role with Eisai Co., Ltd and Chordia Therapeutics, Inc. SO is also a stockholder in Asahi Genomics Co., Ltd., and has received honoraria from The Mitsubishi Foundation and the Nakatani Foundation. Additionally, SO reports receiving grant\/research funding from Chordia Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd, and Nippon Shinyaku Co., Ltd. YN has received grant\/research funding from Daiichi Sankyo Co., Ltd., ThinkCyte Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. YN has also received honoraria from Bristol Myers Squibb Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Novartis Pharma Co., Ltd., Pfizer Japan Co., Ltd., Nippon Shinyaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and AstraZeneca Co., Ltd. The remaining authors declare no competing financial interests related to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}